Insulet

Insulet R&D / Revenue

The R&D to Revenue Ratio of Insulet (PODD) as of Oct 30, 2026 is 11.12 %. In the previous year, R&D to Revenue Ratio was 10.60 % — a change of 4.89% (higher).

R&D / Revenue

11.12 %

YoY

4.89%

Last updated:

R&D to Revenue Ratio of Insulet is 2025 11.12 % . R&D to Revenue Ratio of Insulet was 2024 10.60 % . It decreases by 4.89% higher compared to the previous year.

The Insulet R&D / Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D / Revenue
Date
R&D / Revenue
Jan 1, 2018
15.72 USD
Jan 1, 2019
17.92 USD
Jan 1, 2020
16.23 USD
Jan 1, 2021
14.57 USD
Jan 1, 2022
13.81 USD
Jan 1, 2023
12.08 USD
Jan 1, 2024
10.60 USD
Jan 1, 2025
11.12 USD
The Insulet R&D / Revenue history
YEARR&D / RevenueYoY
11.12 %+4.89%
10.60 %-12.24%
12.08 %-12.50%
13.81 %-5.25%
14.57 %-10.23%
16.23 %-9.43%
17.92 %+14.04%
15.72 %-2.11%
16.05 %+5.75%
15.18 %-7.29%
16.37 %+69.44%
9.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Insulet Stock analysis

What does Insulet do? Insulet Corp is an American company that was founded in 2000 and is headquartered in Acton, Massachusetts. Its goal is to improve the quality of life for people with diabetes by developing innovative products that make living with this chronic disease easier. Insulet Corp is known for its product "OmniPod." The OmniPod is a wireless, portable disposable insulin pump system that offers an alternative option to traditional pumping and insulin delivery systems. The OmniPod system consists of two small devices: a pod worn on the skin and a PDM (Personal Diabetes Manager) that regulates insulin delivery. The pod contains an insulin reservoir that communicates wirelessly with the PDM. The insulin dose is administered directly into the body without needles or tubes. Insulet Corp is also introducing the "OmniPod DASH System." This new system combines the proven design of the OmniPod pod with a new color touchscreen handheld device that allows for even easier operation. The DASH system also offers the ability to control insulin dosing from a smartphone, which can be taken with diabetics wherever they go. The success of the OmniPod system has made Insulet Corp a leading company in the diabetes industry. The company has also developed and introduced products and services in other areas of diabetes treatment. Insulet Corp has developed another product called "Amigo." This product is a personalized travel and training program for people who require insulin. Amigo offers specialized and personalized training to support diabetics in managing complex situations. It also offers diet and exercise plans to make living with diabetes easier. Insulet Corp has also developed a software called "OmniPod Horizon." This software is a closed-loop system that automatically adjusts insulin dosing to keep blood sugar levels within the target range. The system is currently in the development phase and is expected to be released in 2020. Insulet Corp has also developed a program called the "OmniPod Partner Program," which targets doctors and pharmacists. The program provides training and educational materials for healthcare providers to help them better treat and manage their patients. Since 2009, Insulet Corp has been listed on the NASDAQ stock exchange and has continuously evolved since then. The company currently has over 1500 employees and operates in North America, Europe, and the Middle East. Insulet Corp is a company focused on the development of innovative, life-changing products and services. It is expected to continue to play a significant role in improving the quality of life for people with diabetes in the future. Insulet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Insulet stock

R&D to Revenue Ratio of Insulet is 11.12 % in 2025.

R&D to Revenue Ratio of Insulet changed from 10.60 % to 11.12 %, representing a 4.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D to Revenue Ratio Insulet since 2006 – with annual values, charts, and detailed analysis.

The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.

A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's Insulet with sector peers and the industry average to assess whether it is attractive.

To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Insulet

All Key Metrics — Insulet